NUMIF.US Numinus Wellness Inc
- Market cap
- USD 4.17M
- P/E
- -
- P/B
- 1.92x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to May 2025.
Is NUMIF.US undervalued?
Graham numberThe Graham number of Numinus Wellness Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Numinus Wellness Inc fundamental analysis
No fundamental analysis for Numinus Wellness Inc yet.
Numinus Wellness Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Numinus Wellness Inc
Numinus Wellness Inc. provides psychedelic-assisted therapy training, lab testing, and psychotherapy services in Canada and the United States. The company operates through Clinical Research Operations and Practitioner Training segments. It also provides clinical research management services to academic institutions and biotechnology companies. In addition, the company engages in the provision of education and training for research and drug development organizations to suppor…
Full company profileNuminus Wellness Inc financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 3 quarters up to May 31, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Numinus Wellness Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 107K | 881K | 1.51M | 6.49M | 3.75M | 4.17M | 7.11M |
| Gross Profit | - | -252K | 88.0K | -81.5K | 1.78M | 1.59M | 1.17M | 3.19M |
| Operating Income | - | -6.33M | -7.27M | -15.8M | -28.5M | -22.4M | -11.7M | -4.49M |
| EBITDA | - | -6.68M | -8.84M | -17.9M | -42.9M | -22.1M | -13.9M | - |
| Net Income | - | -7.27M | -9.60M | -18.8M | -44.9M | -30.3M | -19.6M | -14.8M |
| EPS | - | - | -0.10 | -0.09 | -0.18 | -0.11 | -0.06 | -0.05 |
| Balance Sheet | ||||||||
| Total Assets | - | 3.08M | 5.12M | 64.1M | 52.6M | 24.3M | 10.8M | 4.29M |
| Total Liabilities | - | 1.71M | 2.32M | 3.31M | 11.4M | 10.3M | 10.0M | 5.84M |
| Shareholders' Equity | - | 1.37M | 2.80M | 60.8M | 41.2M | 14.0M | 725K | -1.55M |
| Cash & Short-term Investments | - | 90.0K | 1.63M | 59.3M | 33.0M | 8.58M | 1.96M | 823K |
| Cash Flow | ||||||||
| Operating Cash Flow | -1.34M | -3.76M | -5.36M | -15.6M | -26.2M | -29.8M | -17.5M | -3.25M |
| Capital Expenditure | 1.76M | 875K | 35.2K | 642K | 1.25M | 232K | 25.5K | 0.00 |
| Free Cash Flow | - | -4.64M | -5.39M | -16.2M | -27.5M | -30.0M | -17.5M | -3.46M |
| Ratios | ||||||||
| ROE | - | -532.0% | -342.9% | -30.9% | -108.9% | -215.4% | -2,707.8% | - |
| ROA | - | -236.0% | -187.4% | -29.3% | -85.3% | -124.3% | -182.3% | -344.5% |
| Net Profit Margin | - | -6,763.1% | -1,089.5% | -1,240.3% | -691.1% | -806.2% | -471.2% | -207.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Numinus Wellness Inc dividends
Numinus Wellness Inc has not paid dividends in the last 7 fiscal years.
Last stock split: 1:2 on May 20, 2020.
Who owns Numinus Wellness Inc
- Insiders 3.50%
- Institutions 1.49%
- Public & others 95.01%
- Shares outstanding 321M
- Free float 309M
Numinus Wellness Inc company profile
- Company name
- Numinus Wellness Inc
- Ticker
- NUMIF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Fiscal year end
- August
- Address
- 250 - 997 Seymour Street, Vancouver, BC, Canada, V6B 3M1
- Phone
- 236 439 3098
- Website
- numinusnetwork.com
About Numinus Wellness Inc
Numinus Wellness Inc. provides psychedelic-assisted therapy training, lab testing, and psychotherapy services in Canada and the United States. The company operates through Clinical Research Operations and Practitioner Training segments. It also provides clinical research management services to academic institutions and biotechnology companies. In addition, the company engages in the provision of education and training for research and drug development organizations to support clinical trials and commercialization efforts. The company serves biotechnology and pharmaceutical companies, research institutions, and healthcare professionals. The company was formerly known as Salvation Botanicals Ltd. and changed its name to Numinus Wellness Inc. in May 2020. Numinus Wellness Inc. is headquartered in Vancouver, Canada.
Numinus Wellness Inc management
9- Mr. Payton NyquvestCo-Founder, CEO & Executive Chair
- Mr. Michael Tan M.B.A.Co-Founder, COO & Director
- Dr. Paul Thielking M.D.Chief Science & Medical Officer
- Dr. Reid J. Robison M.D., MBAChief Clinical Officer · born 1977
- Mr. Kelvin Yang CPAChief Financial Officer
- Mr. Ian NobleChief Communications Officer
- Ms. Lea BottoniVice President of People & Culture
- Ms. Judy Varga M.Sc.Head of Laboratory Operations
- Mr. Jason LapenseeSenior Vice President of Clinic Operations